Stockwinners Market Radar for November 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:58 EST Veeva director sells $977.6K in common stock - In a regulatory filing, Veeva disclosed that its director Matthew Wallach sold 5K shares of common stock on November 6th in a total transaction size of $977.6K.

18:48 EST Tanger Factory CEO: We're repositioning our assets - In an interview on CNBC's Mad Money, Stephen Yalof said, "We're trying to speak to a customer who wants to shop a little differently. We're repositioning our outlets and putting them in new markets." New shops are getting the customer to visit more frequently and spend more, he noted. There's room to grow across America he added.

18:05 EST Mosaic provides 2024 market outlook - "Global grain and oilseed markets are expected to remain tight well into 2024. Crop production, threatened by geopolitical unrest, weather extremes and reduced fertilization, is struggling to keep up with strong demand driven by secular demographic changes and growing consumption from renewable fuels. As a result, global stocks-to-use ratios for grains and oilseeds are expected to remain under pressure for the foreseeable future. Today's constructive agriculture back drop and favorable economics incentivize growers to maximize yields. After two years of under application, growers are seeking to replenish soil nutrients. In North America, a robust spring application season was followed by a successful summer fill program and very strong fall application. Brazil's Safra season led to a recovery of shipments and lower inventories, particularly for phosphate fertilizers. Across most major growing regions around the world, inventories of potash and phosphates have been depleted and will need to be replenished in 2024. Potash supply remains uncertain. Belarusian exports in 2023 are expected to be down 3-4 million tonnes from pre-sanction levels, and only modest increases are expected for 2024 exports. Logistical constraints and geopolitical events are limiting other producers' ability to make up the shortfall. In phosphates, China's exports are expected to remain capped as domestic agriculture and industrial demand is prioritized over fertilizer exports. These factors together suggest global phosphates and potash markets will remain tight through the rest of the year and into 2024."

18:00 EST Lumos Pharma announces OraGrowtH210, OraGrowtH212 meet all endpoints - Lumos Pharma announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic trial met all primary and secondary endpoints. Data from the OraGrowtH210 Trial demonstrated annualized height velocity, or AHV, on the 1.6 mg/kg dose of orally administered LUM-201 of 8.2 cm/yr at six months and 8.0 cm/yr at 12 months on treatment, in line with historical data in moderate pediatric growth hormone deficiency, or PGHD, patients and within the targeted 2 cm/yr margin of the comparator injectable recombinant growth hormone, or rhGH arm. Data also provided preliminary validation of the predictive enrichment marker, or PEM, strategy, with prespecified primary and secondary outcomes met, de-risking our patient selection for our Phase 3 program. Data from the OraGrowtH212 Trial confirmed that LUM-201's unique pulsatile mechanism produces an increase in growth rates while restoring growth hormone secretion and IGF-1 to within normal ranges , with levels substantially below those produced by exogenous injectable rhGH. Additionally, data from a small subset of 10 subjects combined 1.6 and 3.2 mg/kg dosage of LUM-201 in both OraGrowtH210 and OraGrowtH212 trials demonstrated the sustained effectiveness of AHV up to 24 months. Furthermore, the safety profile for LUM-201 remained clean throughout both Phase 2 studies, with no safety concerns identified in either of our Phase 2 trials conducted thus far. Dosage at 1.6 mg/kg demonstrates highest LUM-201 AHV at six months and 12 months 1.7 cm/yr difference between 1.6 mg/kg LUM-201 dose and rhGH comparator arm at 12 months falls within historical non-inferiority Phase 3 margins LUM-201 AHVs align with historical growth rates of rhGH in patient populations with similar characteristics. 12-month AHV data available for 50/81 subjects: Growth rates durable at 12 months. The mean AHVs at six months and 12 months observed in the 1.6 mg/kg dose LUM-201 arm were 8.2 cm/yr and 8.0 cm/yr, respectively. These AHVs were in line with the Company's expectations for 8.3-8.6 cm/yr AHV observed after 12 months of rhGH treatment in a moderate PGHD patient population. The higher than anticipated AHV seen in this moderate PGHD population treated in the rhGH control arm of the OraGrowtH210 Trial was inconsistent with multiple historical trials which predicted growth in the 8.3-8.6 cm/yr range for moderate PGHD1-4. This distinctive growth pattern observed in the daily GH arm of this study is likely due to a higher dosage and the presence of outliers. We anticipate that in a larger, more statistically robust Phase 3 trial, the AHV associated with rhGH treatment will align more closely with historical values for the moderate patient population. The OraGrowtH210 Trial met the prespecified percent responder enrichment providing preliminary validation of the PEM strategy. Additionally, we have achieved a 100% success rate in meeting the predetermined outcome for positive PEM specification classification reproducibility. The topline results from the OraGrowtH212 Trial reveal that LUM-201 achieved an expected AHV with only 20% of the growth hormone, or GH, concentration observed using injectable rhGH. This outcome was achieved through LUM-201's natural pulsatile mechanism, promoting growth in moderate PGHD subjects that align with historical norms. Notably, LUM-201 raised circulating GH to levels closer to normal physiological ranges, whereas treatment with injectable rhGH has been shown to elevate GH levels to four to five times that of typical healthy children. Furthermore, it's important to highlight that during the first 12 months of LUM-201 treatment, no IGF-1 values exceeded 2 standard deviations from the mean. Eighteen and 24-month growth data were available for 10 subjects from the OraGrowtH210 and OraGrowtH212 Trials who met AHV criteria per protocol at 12 months. Combined data from the 1.6 mg/kg and 3.2 mg/kg cohorts of both trials demonstrate sustained AHVs from 12 to 24 months without a considerable decline in growth velocity compared to the previously reported ~20% decline in AHV on rhGH from 12 to 24 months observed in the Pfizer Phase 4 KIGS dataset. The topline results from both the OraGrowtH210 and OraGrowtH212 trials have shown a clean safety record, characterized by an absence of treatment-related Serious Adverse Events, or SAEs, no instances of participants discontinuing treatment due to adverse events, or AEs, and the absence of any significant safety concerns in various parameters such as laboratory values, adverse event data, or in electrocardiogram readings.

17:55 EST Sleep Number says 'surprised' by fall off in consumer demand in Q3 - Expects FY24 gross margin to approach 60%.

17:53 EST Flywire acquires StudyLink, terms undisclosed - Flywire announced that it has acquired StudyLink, an provider of international student admissions, application and agent management software serving universities throughout Australia. Flywire intends to expand upon StudyLink's existing and successful track record of providing top-tier solutions in Australia, where Flywire estimates that there are more than 600,000 higher education international students, with 75% of them being placed through education agents. The combination of StudyLink's application and enrollment platform with Flywire's software and payments technology is expected to capture and streamline the entire student payment journey, from admissions through to deposit and tuition payments, as well as strategic payables like agent commissions. In connection with the acquisition, Flywire will also expand its existing relationship with Navitas, the previous majority owners of StudyLink, as a payments partner for Navitas's campuses and colleges worldwide.

17:49 EST Organon, Samsung Bioepis announce FDA acceptace for review of Hadlima sBLA - Samsung Bioepis and Organon announced that the FDA has accepted for review the supplemental biologics license application, or sBLA, for the interchangeability designation for Hadlima injection 40 mg/0.4 mL, a biosimilar to Humira. The sBLA was submitted to the FDA by Samsung Bioepis in August 2023.

17:45 EST BigBear.ai to acquire Pangiam for $70M - BigBear.ai announced a definitive merger agreement to acquire Pangiam. The purchase consideration is approximately $70M on a cash-free, debt-free basis in an all-stock transaction. The proposed acquisition is expected to close in the first quarter of 2024, subject to customary closing conditions, including approval by the holders of a majority of BigBear.ai's outstanding common shares and receipt of regulatory approval.

17:28 EST National Bank increases quarterly cash dividend 3.8% to 27c per share - National Bank announced that its board of Directors approved a cash dividend to shareholders. The quarterly cash dividend will increase 3.8% from twenty-six cents to twenty-seven cents per share of common stock. The dividend will be payable on December 15, 2023 to shareholders of record at the close of business on November 24.

17:27 EST GoPro says expect to be profitable in Q4 again - The company states: "Based on the full-year outlook provided today, revenue and unit sales for 2023 are expected to be ahead of what we estimated on our Q2'23 earnings call. We returned to year-over-year unit growth in the third quarter at 16% and expect unit growth to be up approximately 15% year-over-year in the fourth quarter. We increased door count by 13% since the second quarter. Through October, we are tracking to our estimated 1 million units of camera sell-through in the fourth quarter. We returned to non-GAAP profitability in the third quarter and expect to be profitable on a non-GAAP basis in the fourth quarter. These are very positive, early signs that our plans to return GoPro to growth and profitability are working... Our success in selling more of our entry-level products than initially projected has put pressure on near-term gross margins. We expect margin pressure to continue through Q1 2024 until the replacement of our current low margin entry-level products with a newly designed entry-level camera at a lower product cost expected in the second quarter of 2024. We continue to invest in innovation, notably in system-on-chip, hardware, accessories and software. In addition, we are expanding marketing and sales capabilities to fuel growth, while also driving efficiencies in other areas of the business. We have prudently tightened operating expenses for 2023, which we expect to be at $365 million, down from $370 million estimated during our last earnings report."

17:25 EST Sleep Number expects 'significantly lower' CapEx in FY24

17:19 EST Ovintiv sees Q4 capital investments $660M-$700M

17:16 EST Sleep Number says industry demand weakened 'significantly' in Q3 - Says holding media spend below prior years' levels. Expects to achieve positive cash flow in 2024. Says innovation pipeline "remains robust." Says focused on paying down debt. Comments taken from Q3 earnings conference call.

17:10 EST Heliogen announces suspension of NYSE listing status - Heliogen "announced it has received notice that the New York Stock Exchange has determined to suspend trading of - and commence proceedings to delist - shares of Heliogen's common stock and public warrants, effective immediately. This suspension was made because the Company fell below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15 million. The Company intends to appeal the delisting determination. Heliogen anticipates that its common stock and public warrants will begin trading in the over-the-counter marketplace on November 8, 2023 under the symbols HLGN and HLGNW, respectively."

17:06 EST Nintendo to develop live-action 'Legend of Zelda' film - Nintendo (NTDOY) announced that it will develop a live-action film of "The Legend of Zelda." The film will be produced by Shigeru Miyamoto, Representative Director and Fellow of Nintendo and Avi Arad, Chairman of Arad Productions Inc., who has produced many mega hit films. The film will be produced by Nintendo and Arad Productions Inc., and directed by Wes Ball. The film will be co-financed by Nintendo and Sony Pictures Entertainment Inc. (SONY), with more than 50% financed by Nintendo. The theatrical distribution of the film will be done worldwide by Sony Pictures Entertainment Inc.

17:00 EST Arthur J. Gallagher to acquire The Evans Agency - Arthur J. Gallagher & Co. (AJG) announced it has signed a definitive agreement to acquire Williamsville, New York-based The Evans Agency, a wholly-owned subsidiary of Evans Bancorp (EVBN). The transaction is expected to close during the Q4. The Evans Agency is a commercial property/casualty insurance broker with public entity and scholastic expertise, serving clients throughout Western New York. The agency also offers personal lines and employee benefits services. Aaron Whitehouse and his team will operate under the direction of Patrick Kennedy, head of Gallagher's Northeast region retail property/casualty brokerage operations.

16:58 EST Akamai sees FY23 operating margin 29% - Sees FY23 tax rate 17%. Sees FY23 capital expenditures 19% of revenue.

16:57 EST Assured Guaranty names current CFO Robert Bailenson as next COO - Assured Guaranty announced that, as of January 1, 2024, Chief Financial Officer Robert A. Bailenson will be appointed Chief Operating Officer, and Chief Actuary Benjamin G. Rosenblum will succeed him as Chief Financial Officer. As CFO, Mr. Rosenblum will assume responsibility for the operations of critical financial functions. As Chief Actuary, he has already been leading the Accounting, Financial Reporting, Sarbanes-Oxley controls, Portfolio Analytics and Quantitative Analytics departments and will continue to do so as CFO. In addition, he will oversee Treasury, Tax, and Investment Management.

16:52 EST F&G Annuities expands share repurchase plan by $25M - F&G Annuities & Life announced that its Board of Directors has increased the company's share repurchase authorization by $25M to an aggregate of $50M. From inception of the share repurchase program on March 21, 2023 to November 6, 2023, the company has repurchased 868,930 shares of common stock for $18.3M, at an average price of $21.07 per share. This brings the total remaining authorization to approximately $31.7M.

16:49 EST Sleep Number falls 40% to $9.70 after Q3 results miss, FY23 EPS view cut

16:45 EST Koru announces FDA clearance for FREEDOM60 with prefilled syringes - Koru Medical Systems announced that it received Food and Drug Adminisration clearance for use of the FREEDOM60 Infusion System with Hizentra 50 mL prefilled syringes. "The FREEDOM Infusion System is the first and only infusion system cleared for use with prefilled syringes and, given the majority of patients are prescribed doses of 50 mL or greater, this clearance for FREEDOM60 significantly expands the benefits of PFS use, especially for those diagnosed with conditions requiring significantly higher doses of immunoglobulin," the company said in a statement.

16:40 EST Nacco Industries announces $20M stock repurchase program - Nacco's Board of Directors approved a stock repurchase program providing for the purchase of up to $20M of the company's outstanding Class A Common Stock through December 31, 2025. Nacco's current program would have expired on December 31, 2023 but has been terminated and replaced by the new program. Since the adoption of the prior program in November 2021, the company has expended approximately $1.5M to purchase approximately 45,000 shares of Class A Common Stock.

16:37 EST IPG Photonics, Miller Electric Mfg. announce technology collaboration - Miller Electric Mfg., a worldwide manufacturer of arc welding products, and IPG Photonics, announced a strategic technology partnership with a goal to further promote laser solutions for handheld welding applications. The combination of Miller's extensive knowledge of the unique needs of traditional welding methods and IPG Photonics' expertise in fiber laser technology will bring ease of use, speed and precision, transforming the handheld welding process. This partnership will usher in a new era of handheld welding solutions, offering welders access to next-generation laser technology by understanding and addressing their unique needs, ensuring that solutions are customized to suit their specific requirements. Both companies bring unique expertise to develop specific solutions to address customer challenges, and together they will further advance and bring to market products which are easy to learn and operate while offering unmatched benefits.

16:34 EST F&G Annuities raises quarterly dividend 5% to 21c from 20c per share - The dividend will be payable December 29 to stockholders of record as of December 15.

16:33 EST NYSE to commence delisting proceedings against Heliogen - The New York Stock Exchange announced that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities of Heliogen from the NYSE. Trading in the company's securities will be suspended immediately. NYSE Regulation reached its decision to delist the company's securities pursuant to Section 802.01B of the NYSE's Listed Company Manual because the company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15M. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the securities upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision.

16:32 EST Myomo says positioned for product revenue growth in Q4 - The company states: "Based on the size of the patient pipeline entering the fourth quarter, we expect another strong quarter of insurance authorizations and orders for the MyoPro. The realized revenue for the quarter will depend on the payer mix, the timing of MyoPro deliveries and the receipt of reimbursement payments from insurers. With the backlog up modestly on a sequential basis, and assuming a typical number of 'in-quarter' fill orders, we believe we are positioned for year-over-year product revenue growth for the fourth quarter. In addition, we expect the full year product revenue growth to be consistent with the growth rate through the first nine months of the year, which is within our target range of 20-30% growth stated at the beginning of the year."

16:30 EST Durect falls 71% to 75c after Phase 2B study misses primary endpint

16:30 EST Sleep Number trading resumes

16:29 EST Turtle Beach raises FY23 adjusted EBITDA view to $8M-$10M from $6M-$8M - Turtle Beach states: "The Company is pleased to report performance ahead of schedule and continues to execute on a number of initiatives to improve efficiency and profitability including SKU rationalization, portfolio optimization, platformed product development and more. As a result of the Company's better than expected performance, the Company is raising its Adjusted EBITDA outlook for fiscal year 2023 and now expects to be in the range of $8 million to $10 million, versus the $6 million to $8 million range stated previously. Additionally, given the improving line of sight into the impact of various cost savings initiatives, the Company now expects to exit 2023 with a run rate Adjusted EBITDA in the range of $28 million to $33 million, an increase from a 2023 exit run rate Adjusted EBITDA range of $25 million to $30 million just a quarter ago."

16:25 EST PGT Innovations names Craig Henderson as new CFO - PGT Innovations "announced the appointment of Craig Henderson as Senior Vice President and Chief Financial Officer, effective October 31, 2023. As Chief Financial Officer, Henderson will lead the company's finance strategy, budgeting and planning, accounting, financial reporting, and investor relations functions. Henderson joined PGT Innovations in 2021 as Vice President of Finance, with responsibilities for leading the company's budgeting and planning and investor relations functions, and has been serving as interim Chief Financial Officer since February 2023."

16:23 EST Durect says AHFIRM study missed primary endpoint of mortality - Durect announced topline results from its AHFIRM trial, a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of larsucosterol in 307 patients with severe alcohol-associated hepatitis. Both the 30 mg and 90 mg larsucosterol doses demonstrated a "compelling and clinically meaningful" trend in reduction of mortality at 90 days, the key secondary endpoint, with mortality reductions of 41% in the 30 mg arm and 35% in the 90 mg arm compared with standard of care, the company said in a statement. The numerical improvement in the primary endpoint of mortality or transplant at 90 days did not achieve statistical significance for either dose of larsucosterol. Both doses of larsucosterol showed a more pronounced reduction in mortality in patients enrolled in the U.S., representing 76% of patients enrolled in the trial, Durrect added. The reductions in mortality at 90 days were 57% for the 30 mg arm and 58% for the 90 mg arm compared with SOC. Larsucosterol was safe and well tolerated, according to the company. Durect intends to have an End of Phase 2 meeting with the Food and Drug Administration to discuss the trial results and the Phase 3 registration trial design in Q1 of 2024. "The topline results from AHFIRM provide compelling evidence that administration of larsucosterol can reduce mortality at 90 days in this devastating disease," said James Brown, CEO of Durect.

16:15 EST Rivian increases 2023 production guidance to 54,000 total units - Rivian said: "Due to the progress experienced on our production lines, the ramp of our in-house motor line, and the supply chain outlook, we are increasing our 2023 production guidance to 54,000 total units. Our progress on cost management has also continued and therefore we are improving our Adj. EBITDA guidance to $(4,000) million. We are also lowering our capital expenditures guidance to $1,100 million."

16:14 EST Sun Country Airlines announces additional $25M for repurchases -

16:10 EST Dutch Bros sees FY23 adjusted EBITDA $150M-$155M - The company said, "Dutch Bros is providing the following guidance for the year 2023: Our expectation for total system shop openings in 2023 remains unchanged. We expect to open at least 150 new shops, of which at least 130 will be company-operated. Our expectation for capital expenditures remains unchanged, which we expect to be in the range of $225 million to $250 million. This includes approximately $15 million to $20 million in spending in 2023 for a new roasting facility, which is projected to open in 2024. Our estimate of system same shop sales growth in the low single digits remains unchanged. Our expectation that revenue would be at the lower end of the range of $950 million to $1 billion remains unchanged. Given the strength of company-operated shops and continued SG&A leverage, we now estimate Adjusted EBITDA will be between $150 million to $155 million, up $15 million from last quarter. This reflects stronger than expected year-to-date profitability in Q3, partially offset by the increased shop labor investments in the range of $1.5 million to $2.0 million as well as certain investments we intend to make in business building activities throughout the fourth quarter."

16:06 EST Heliogen trading halted, news pending

16:03 EST Amgen reports data from Phase 2 study evaluating dazodalibep - Amgen announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjogren's. These results will be featured in presentations at the American College of Rheumatology Convergence, Nov. 10-15, in San Diego. Findings from the study demonstrate that dazodalibep may improve both the systemic and symptomatic disease burden of two different patient populations. The Phase 2 study of dazodalibep, a CD40 ligand antagonist in clinical development, was a randomized, double-blind, placebo-controlled crossover study evaluating two Sjogren's populations: patients with moderate to severe systemic disease activity and those with moderate to severe symptomatology despite lacking additional organ involvement. The company is advancing a Phase 3 trial evaluating the benefit of dazodalibep in Sjogren's. The first patient population included patients with moderate to severe systemic disease activity as defined by a EULAR Sjogren's Syndrome Disease Activity Index score greater than or equal to5. Key findings include: Patients who transitioned from placebo to dazodalibep experienced an improvement in their disease activity from Day 169 to Day 365; at Day 365, patients who transitioned to dazodalibep also showed greater improvements in ESSDAI response rate, EULAR Sjogren's Syndrome Patient Reported Index score and fatigue compared to those who transitioned to placebo. Dazodalibep was generally safe and well tolerated. The second patient population studied included those with moderate to severe symptomatology including dryness, fatigue and pain despite lacking additional organ involvement as defined by an ESSPRI score greater than or equal to5 and an ESSDAI score of less than5. Key findings include: Patients who transitioned from placebo to dazodalibep experienced further improvement in total ESSPRI score from Day 169 to Day 365; for patients who transitioned from dazodalibep to placebo, the improvements in total ESSPRI score achieved at Day 169 were largely sustained through Day 365; patients who transitioned to dazodalibep also showed improvements in measurements of fatigue and the Patient Global Impression of Severity from Day 169 to Day 365.

16:01 EST Veracyte enters In Vitro diagnostic agreement with Illumina - Veracyte (VCYT) today announced that it has entered into a multi-year agreement with Illumin (ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina's NextSeq 550Dx next-generation sequencing instrument. The agreement is part of Veracyte's expanded, multi-platform IVD approach, which will also include qPCR and is designed to accelerate the company's ability to make its tests available to more patients globally. The first tests that Veracyte plans to develop for the Illumina NextSeq 550Dx instrument are its Prosigna Breast Cancer Assay and Percepta Nasal Swab test. Prosigna is already commercially available as an IVD test that helps inform treatment decisions for patients with early-stage breast cancer. The noninvasive Percepta Nasal Swab test is intended to help guide diagnosis and treatment decisions for current and former smokers with lung nodules that are potentially cancerous.

16:00 EST Durect trading halted, news pending

15:29 EST Apollo Senior Floating Rate Fund trading resumes

15:21 EST Cameco trading resumes

15:02 EST MidCap Financial Investment Corp trading halted, news pending

14:59 EST Data Knights Acquisition Corp trading halted, volatility trading pause

13:46 EST Apollo Senior Floating Rate Fund trading halted, news pending

13:45 EST Salesforce says Dreamforce conference to return to San Francisco - Salesforce announced in a post on X, formerly Twitter, that its Dreamforce conference for customers and partners will return to San Francisco, California for Dreamforce 2024. "See you in San Francisco on September 17-19, Trailblazers," the company said. Reference Link

12:37 EST Syntec Optics completes business combination OmniLit Acquisition - Syntec Optics announced that it completed its business combination with OmniLit Acquisition Corp. (OLIT). The combined company will operate under the name Syntec Optics Holdings. Commencing, November 8, Syntec's common stock and warrants are expected to trade on the Nasdaq Stock Exchange under the symbols "OPTX" and "OPTXW," respectively. The transaction was approved by OmniLit's shareholders at a special meeting held on October 31. Syntec Optics says it is one of the largest custom optics and photonics manufacturers in the United States

12:12 EST CFPB proposes federal oversight of providers of digital wallets, payment apps - The Consumer Financial Protection Bureau, or CFPB, is proposing to supervise larger nonbank companies that offer services like digital wallets and payment apps. "Driven largely by Big Tech and other large technology firms, digital payment apps and wallets continue to grow in popularity, but many of the companies are not subject to CFPB supervisory examinations. The rule proposed today would ensure that these nonbank financial companies - specifically those larger companies handling more than 5 million transactions per year - adhere to the same rules as large banks, credit unions, and other financial institutions already supervised by the CFPB," the Bureau stated. "Payment systems are critical infrastructure for our economy. These activities used to be conducted almost exclusively by supervised banks. Today's rule would crack down on one avenue for regulatory arbitrage by ensuring large technology firms and other nonbank payments companies are subjected to appropriate oversight," added CFPB Director Rohit Chopra. Today's proposed rule, if finalized, would be one part of the CFPB's efforts to carefully monitor the entry of large technology firms, including Big Tech giants, into consumer financial markets. Publicly traded tech companies with digital wallets and payment apps include Block (SQ), PayPal (PYPL), Apple (AAPL), Amazon (AMZN) and Alphabet (GOOGL). Reference Link

12:00 EST Cano Health falls -15.0% - Cano Health is down -15.0%, or -$1.81 to $10.26.

12:00 EST Ameresco falls -23.6% - Ameresco is down -23.6%, or -$6.28 to $20.33.

12:00 EST Alteryx rises 20.4% - Alteryx is up 20.4%, or $6.19 to $36.53.

11:49 EST FSD Pharma updates on proposed Celly Nutrition dividend distribution - FSD Pharma announces that the company, "in the upcoming weeks," will be announcing the record date for the company's special dividend of shares of Celly Nutrition Corp., or "Celly Nu," the holder of exclusive rights to FSD Pharma's recreational alcohol misuse technology. "Led by beverage and marketing icons, Celly Nu is actively developing a first-in-class product that has been shown to effectively expedite alcohol metabolism. In the coming weeks shareholders of FSD Pharma will become shareholders in Celly Nu, assuming all customary conditions and approvals are achieved. The company believes this will be an optimal way to return value to its shareholders considering the structure of the licensing agreement between Celly Nu and FSD Pharma. Going forward, FSD Pharma shareholders, Celly Nu shareholders - which include Kevin Harrington and Gerry David - and both companies will be aligned to potentially capitalize on successes of Celly Nu. FSD Pharma shareholders will not only benefit from the growth of Celly Nu with the development and sales of products to organically build value, they will concurrently participate in the growth of FSD Pharma, which is entitled to a 7% royalty on all future gross revenue Celly derives from sales of products using the company's technology," FSD Pharma stated.

11:19 EST Hindenburg says EHang has 'major credibility issue,' last in line for takeoff - In a recently published report titled "EHang: Hollow order book and fake sales make this China-based eVTOL company last in line for takeoff," Hindenburg research says "the company is a fatal accident waiting to happen, both for investors and for passengers." According to Hindenburg, EHang (EH) has generated net losses since inception and currently trades at about 50.3-times its tangible book value, a significant premium to competitors Joby Aviation (JOBY) and Archer Aviation (ACHR). "Despite its premium valuation, EHang's flagship aircraft is outmatched by competitors on key performance metrics," it adds. "Overall, EHang seems to have a major credibility issue - whether it be by fluffing up its preorder book (which looks to almost entirely be vapor) or by brazenly misleading about early sales that bear all the hallmarks of fake revenue," the report said. Shares of EHang have dropped over 13% to $12.98 in Tuesday morning trading. Reference Link

11:11 EST EHang falls 13% to $13 after Hindenburg Research short report

10:59 EST Turkcell trading resumes

10:40 EST Adtran suspends dividend to reduce expense, support long-term capital plan - Company says taking steps to become a leaner company, including the discontinuation of legacy non-core product. Decision to suspend quarterly dividend to reduce interest expense and support its long-term capital plan "didn't come lightly." "We're in a period of market uncertainty," which resulted in a more cautious forecast, the company said. Comments taken at Adtran's earnings call.

10:29 EST Northann Corp trading resumes

10:26 EST Royalty Management Holding Corp trading resumes

10:24 EST Northann Corp trading halted, volatility trading pause

10:17 EST Korro Bio Inc trading resumes

10:00 EST CNH Industrial falls -11.8% - CNH Industrial is down -11.8%, or -$1.33 to $10.01.

10:00 EST Ameresco falls -27.3% - Ameresco is down -27.3%, or -$7.26 to $19.35.

10:00 EST Triumph Group rises 15.5% - Triumph Group is up 15.5%, or $1.23 to $9.14.

09:47 EST Net Lease Office falls -12.1% - Net Lease Office is down -12.1%, or -$1.51 to $11.00.

09:47 EST Olo falls -20.7% - Olo is down -20.7%, or -$1.21 to $4.64.

09:47 EST Alteryx rises 17.6% - Alteryx is up 17.6%, or $5.35 to $35.69.

09:41 EST NLOP Stock trading resumes

09:37 EST Digimarc trading resumes

09:36 EST NLOP Stock trading halted, volatility trading pause

09:34 EST reAlpha Tech Corp trading halted, volatility trading pause

09:33 EST BioMarin jumps 8% to $82.58 after Reuters report of Elliott stake

09:31 EST Oportun Financial trading halted, volatility trading pause

09:27 EST TripAdvisor sees FY24 adjusted EBITDA dollar growth outpacing revenue growth - For FY24, TripAdvisor said it expects to deliver adjusted EBITDA dollar growth that will outpace revenue growth due to full year profit contributions from both Viator and TheFork.

09:23 EST Matterport introduces CAD file add-on in advance of Autodesk University - Matterport announced in advance of Autodesk University, a new CAD file add-on that will enable the simple creation of CAD files directly from Matterport digital twins to speed up design workflows using Matterport.Historically, Matterport has only delivered CAD files as part of its BIM file add-on, however for projects that don't require the level of detail of BIM, this added unnecessary time and cost to a project. With the new CAD file add-on, Matterport customers can reduce design and documentation time through a one-click solution producing editable CAD drawings from Matterport point clouds.

09:21 EST TripAdvisor seeing 'compelling' early results from Trips upgrade - TripAdvisor, on its Q3 earnings call, said it is on plan to launch this full trip planning and itinerary product on its mobile app on ioS and Android this quarter.

09:18 EST CNH Industrial receives approval of application to delist from Euronext Milan - CNH Industrial announced it had filed an application with Borsa Italiana to delist the Company's common shares from Euronext Milan pursuant to the Rules of the Markets organized and managed by Borsa Italiana. The Company now announces that Borsa Italiana has approved the Company's application and has arranged for the delisting of the Company's common shares from Euronext Milan, with effect from January 2, 2024, pursuant to Article 2.5.6 of the said Rules. CNH's common shares will continue to be listed also on Euronext Milan until the last business day before the Delisting Date. The single listing on the New York Stock Exchange will therefore be effective starting from the Delisting Date.

09:12 EST Camber Energy announces notices of allowance for additional patents - Camber Energy announced that Viking Protection Systems received Notices of Allowance from the United States Patent & Trademark Office regarding: utility patent application No. 18227670 titled "Electric Transmission Line Ground Fault Prevention Methods Using Multi-Parameter High Sensitivity Monitoring"; and patent application No. 17/821,651 titled "Electric Transmission Line Ground Fault Prevention Systems Using Dual Parameter Monitoring With High Sensitivity Rela Devices in Parallel With Low Sensitivity Relay Devices". The prospective patents relate to Viking Protection's proprietary transmission line ground fault prevention systems and methods, which are designed to detect a break in a transmission line, or coupling failure, and to immediately de-energize the line, thus preventing an energized high voltage transmission line from contacting ground or a grounded structure. The technology is designed to be an integral component within a much-needed, worldwide grid hardening and stability initiative by electric utilities to improve resiliency and reliability of existing infrastructure. Viking Protection's software-based solution can be deployed within a utility's existing protective relay infrastructure, allowing the utility to protect its grid with greater confidence and reliability. Viking Protection is a majority-owned subsidiary of Viking Energy Group, Inc. ("Viking"), a wholly-owned subsidiary of Camber.

09:11 EST Sintx Technologies enters long-term supply agreement for aerospace components - SINTX Technologies announced that it has entered a Long-Term Agreement, LTA, to supply jet engine components made of its silicon nitride. The agreement materialized after a rigorous 2-year qualification of the Company's Operational and Quality Management Systems and manufacturing capabilities, and successful testing of prototype components. "To meet the challenge of making aerospace parts with complex designs, SINTX had to innovate new manufacturing capabilities and processes," said Dave O'Brien, Executive Vice President and Chief Operating Officer at SINTX. "This entailed going beyond our expertise in producing medical implants into manufacturing strong and durable jet engine components under an AS9100D certified quality management system.This LTA is one example of the non-medical opportunities that SINTX is targeting, as the Company seeks to expand its capabilities beyond biomedical implants toward producing industrial and aerospace products. SINTX's Maryland facility, for instance, is making prototypes for several energy and defense applications," added O'Brien.

09:10 EST Hanryu Holdings launches personalized AI assistant DeokGom - Hanryu Holdings announced the launch of a personalized artificial intelligence feature to its global user base in November. FANTOO's flagship digital character, DeokGom, is well-recognized among users and this month will expand its offerings to provide an enhanced user experience. This new feature on FANTOO will be unveiled as a paid-for-service using FANIT and FANTOO POINT that users own. AI DeokGom, with the power of Chat GPT, will interact with users, provide customized services and various Hanryu info to users. Hanryu is working closely with its partner, SALTLUX, to leverage its Goover AI technology to provide real-time news and Fandom info on FANTOO including world news and social media in real-time. Also, the Company will provide advanced AI assistant services to users by analyzing the user's behavior to understand personality, lifestyle, and interests. Based on that data, AI assistant will recommend users' content and other services offerings on FANTOO.

09:09 EST Marathon Digital launches renewably powered bitcoin mining project in Paraguay - Marathon Digital has launched its second international deployment with a 27 megawatt Bitcoin mining project in Paraguay that is completely powered by renewable, hydro energy. The first miners are onsite and currently being prepared for installation and energization. On October 16, 2023, Marathon entered into an agreement with Penguin Infrastructure, whose mission is to transform energy into human potential in Paraguay, to launch a Bitcoin mining project near Paraguay's Itaipu Dam. This project, which is structured as a joint venture, will be built out in two stages. The first stage will utilize approximately seven megawatts to power approximately 0.3 EH/s of Marathon's miners and is expected to be energized in November. The second phase will utilize approximately 20 megawatts to power approximately 0.8 EH/s of Marathon's miners and is expected to come online in 2024. "After proving that we can successfully deploy internationally with our project in Abu Dhabi, we are continuing to expand into new markets with excess or stranded energy," said Fred Thiel, Marathon's chairman and CEO. "This project is our second international deployment and marks our first into Latin America.

09:08 EST Adamas One joins Webull's Corporate Connect Service - Adamas One has begun participating on the Webull Corporate Connect Service. The Adamas One page on the Webull Corporate Connect Service will provide real-time Company updates, important announcements, and other relevant content such as news, earnings reports, investor presentations, marketing materials, industry snapshots and more. Additionally, the Webull platform provides level 2 quotes, after hours trading, robo advisors, fractional shares, trade widgets, enhanced charting tools, educational trading services and much more for their clientele.

09:07 EST ImmunityBio: 1st data for memory cytokine-enriched NK cells in SCLC 'promising' - ImmunityBio announced new data showing that the company's Memory Cytokine-Enriched Natural Killer cells M-ceNK may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors. Findings from the study titled "Characterization of the anti-tumor activity of memory cytokine enriched NK cells or M-ceNK, against tumors with neuroendocrine features" were presented by Kristen Fousek, Ph.D., Research Fellow with the Center for Immuno-Oncology of the National Institutes of Health's National Cancer Institute NCI in a poster session at the annual meeting of the Society for Immunotherapy of Cancer SITC in San Diego, November 4 . Small cell lung cancer or SCLC is an aggressive neuroendocrine,NE, carcinoma and has few treatment options. Although immune checkpoint blockade ICB is approved in combination with chemotherapy in extensive stage disease, only a subset of patients experience an improvement in overall survival. In the new study, the killing capacity of M-ceNK cells was assessed in four SCLC cell lines representing the major molecular subtypes. M-ceNK cells, generated from cells from several healthy donors, were found to express high levels of activating receptors and low levels of inhibitory receptors, as well as elevated IFN-gamma and granzyme B production - all of which are important for anti-tumor activity. .."These results are further evidence of the potential of M-ceNK therapy as a new immunotherapy approach for treating cancers that do not respond to immune checkpoint blockade, the current standard of care," said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. "We are encouraged by the data coming out of this study and we look forward to assessing the potential for M-ceNK therapy in other tumor types."

09:06 EST Connexa Sports Technologies announces expanded patent coverage - Connexa Sports Technologies confirms that Slinger Bag Americas, through its subsidiary company Israeli-based Slinger Bag Limited, the holder of all Slinger Bag intellectual property, has been granted utility and design patents in four key commercial and manufacturing territories, and design patents in three additional territories for its Slinger Bag Ball Launcher. The utility and design patents cover all ball sport verticals and specifically protect the innovation of building a ball launcher into the bottom of a typical roller duffle bag, making the Slinger Bag Ball Launcher one of the most versatile, transportable, and affordable ball machines on the market. "The granting of these utility and design patents underpins our belief that we have 'reinvented tennis' by making the sport significantly more accessible and affordable to both current and new tennis participants, allowing players to take their game to a new level and to encourage more tennis to be played, more often," commented Mike Ballardie CEO, Connexa Sports Technologies.

09:05 EST CareCloud's talkEHR selected by Ultrasound Express - CareCloud announced Ultrasound Express has chosen CareCloud's talkEHR platform to help enhance the patient experience and streamline their administrative processes. "At Ultrasound Express, our core goal is to make ultrasound experiences in our community as comfortable and stress-free as possible," shared Christopher Harper, co-owner of Ultrasound Express. "We understand the concerns that can come with medical tests and waiting for results. That's why we offer same-day appointments and speedy results in a calm and welcoming environment. To support this commitment, we've implemented CareCloud's advanced EHR system that streamlines administrative processes on our side, provide our patients with a smooth and relaxed experience from start to finish."

09:03 EST Data Storage selected to provide cyber security solutions - Data Storage Corporation announces it has been selected to provide cyber security solutions for implementation into one of the nation's leading sports and entertainment companies security systems. "We are honored to have been chosen by this large and nationally recognized client to provide a variety of services and solutions to address their cyber security needs," commented Tom Kempster, president of Data Storage Corporation's Flagship subsidiary. "In particular, our cyber security solution incorporates powerful AI technology with threat intelligence to protect the customer's infrastructures and accelerate incident response capabilities. This is an expansion of our existing relationship with the customer, which we believe validates the quality and reliability of our offerings, as well as our ability to cross-sell services across our product lines. We look forward to future technology modernizations with this client over time."

09:02 EST IBM launches $500M enterprise AI venture fund - IBM announced that it is launching a $500M venture fund to invest in a range of AI companies - from early-stage to hyper-growth startups - focused on accelerating generative AI technology and research for the enterprise. With a differentiated model and strategy consisting of domain expertise from across IBM and a dedicated portfolio development team, the IBM Enterprise AI Venture Fund will invest in current and future AI leaders that are helping businesses around the world realize the potential of AI for business. Led by a dedicated team at IBM with decades of combined experience as highly successful investors and enterprise AI experts, the fund will provide each startup with opportunities to develop meaningful partnerships with IBM, while gaining operational expertise on product and engineering and go-to-market strategies.

08:59 EST PharmAla Biotech completes shipment of MDMA, psilocybin to Cortexa - PharmAla Biotech has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health.This shipment marks the first time that any molecules recently re-scheduled under the Authorized Prescriber Scheme were brought into Australia explicitly for use under that scheme, rather than for clinical trial purposes. The shipment, completed in several parts, includes both psilocybin and MDMA, and contains a both API and finished drug product capsules. The provision of these materials for Cortexa's commercial use, as well as the transfer of relevant intellectual property to Cortexa, allows for Cortexa to subsequently rely on domestic manufacturing within Australia, rather than imports. This should allow for lower cost-of-goods and a shorter time to market , for these products.

08:51 EST Arteris IP awarded ISO 9001 certification for semiconductor system IP system - Arteris announced it has achieved ISO 9001:2015 Quality Management System certification. DEKRA, the world's largest independent expert specializing in the testing, inspection and certification sector, conducted this rigorous assessment. This accomplishment is a significant milestone for Arteris and validates the dedication to consistent quality management across all operations to provide reliable and relevant products and solutions. ISO 9001 is the global standard for creating quality management systems and is developed and published by the International Organization for Standardization. It provides a framework for companies to ensure consistent outcomes when designing, developing, and deploying products and services. "ISO 9001 certification affirms our steadfast commitment to prioritize our customers, deliver exceptional products and maintain robust QMS across our entire organization," said K. Charles Janac, president and CEO of Arteris. "This achievement highlights our ongoing efforts in quality process enhancement, effective risk management and adherence to regulatory compliance for our portfolio of system IP."

08:50 EST Meta Materials announces results from strategic restructuring - Meta Materials announced preliminary positive cost cutting results from the initial stages of restructuring, while signaling its intent to focus on core business lines currently generating revenue and those expected to generate revenue in the not-too-distant future. This update follows the revised operating plan, which was approved by our board of directors on June 6, 2023. With hundreds of patents, multiple production facilities and R&D labs, META's in-house team continues to work on the company's most productive business lines, including: Photonic Material: META's proprietary KolourOptik and LumaChrome anti-counterfeiting security foils have gained broad awareness in the banking industry, with a number of global currency customers in talks. On September 12, 2023, META launched its first fully animated nano-optic banknote security product, QUANTUM stripe based on KolourOptik technology; orders are being accepted from industry partners. On September 20, 2023, META appointed Mark Spencer as SVP of Product & Design for its authentication division. The industry veteran has expertise in banknote design, development and production, having served with De La Rue and Crane Currency. On September 27, 2023, META received $6.2 million in new purchase orders; the larger agreement with a confidential G10 central bank customer spans up to 5 years for up to $41.5M from initiation. Electro-Optics: META's wide area motion imagery platform, VLEPSIS, deploys both proprietary hardware and artificial intelligence to monitor hundreds of objects/locations simultaneously. Applications for this technology include security and surveillance, border monitoring, search and rescue, traffic management, and novel smart city sensing, among others. On November 13-17, 2023, META will be showcasing this latest innovation at the Dubai Airshow. Battery Materials: NCORE current collectors and NPORE battery separators are groundbreaking technologies that increase energy/power density, while improving battery safety. The battery technology results in safer, lighter, more sustainable batteries with broad potential applications, especially in the hybrid and electric vehicle space. In addition to an external partnership with a tier-1 global OEM, the Company is exploring partnerships with a number of battery companies with a target of broad-scale commercialization. On March 20, 2023, META announced a joint development agreement for NPORE battery separator materials with a confidential global Top 10 battery OEMs. In this effort, META plans to spin-off a number of other business lines in order to capture and preserve additional capital for expenses and R&D focused on core products. The company also intends to eliminate redundancies, including overhead and limited non-essential workforce. The expected annualized cost savings will be approximately $20 to 30 million, with additional savings possible as the company continues to right-size facilities and spending.

08:50 EST Verses Technologies announces Cortical Labs as secon beta partner - VERSES AI announced a partnership with Cortical Labs, a biological hardware startup that is seeking to revolutionize computing by fusing live neurons with silicon chips. The partnership between VERSES and Cortical Labs marks an alignment of philosophies around the future of computing between software patterned after algorithms found in nature and hardware constructed from brain cells. Cortical Labs, recently backed by billionaire Li Ka Shing and In-Q-Tel, the venture capital arm of the Central Intelligence Agency, are the creators of DishBrain - a synthetic biological computer consisting of 800,000 neurons, grown in-vitro, capable of performing goal-directed tasks, such as playing the tennis-like computer game Pong.

08:48 EST 22nd Century expands reduced nicotine content tobacco IP - 22nd Century Group announced the signing of an additional reduced nicotine content technology license with North Carolina State University. The latest license provides additional modes of efficiently producing reduced nicotine content tobacco plants, extending 22nd Century's already extensive IP portfolio. The license will provide 22nd Century Group exclusive rights to the technology until 2042. "Our reduced nicotine content technologies support the first and only FDA MRTP authorized combustible smoking harm reduction products that meet adult smokers where they are today, providing a new solution to help them smoke less and achieve their health goals," said John Miller, interim Chief Executive Officer of 22nd Century Group. "This latest license further enhances and expands on our capabilities to produce reduced nicotine content tobacco plants as we work to bring these innovative products to market for the betterment of public health, including by enhancing our capability to produce reduced nicotine content tobacco plants suitable for international markets that are opposed to genetically modified plants." Under terms of the exclusive license, 22nd Century will have full use of the patent rights and plant materials to develop and commercialize reduced nicotine content tobacco using this latest non-GMO technology, which further enables worldwide marketability of the Company's VLN reduced nicotine content products. Financial terms of the agreement were not released.

08:47 EST Uber says consumer activity 'remains robust' - Says U.S. consumer "incredibly strong." Says exiting the year with "tremendous momentum." Says Q3 was "strong across the board." Says has "multiple avenues for growth." Says earnings growing faster than gross bookings. Seeing growth initiatives scale. Says "pretty bullish" on growth trajectory of the company. Expects flat to incremental head count growth going forward. Comments taken from Q3 earnings conference call.

08:46 EST Whitestone REIT adds specialty food component at two open-air shopping centers - Whitestone REIT shares leasing updates for two of its open-air shopping centers in Houston. The Company added Wild Fork, a modern-day meat and seafood market, at Lake Woodlands Crossing, bringing occupancy at the Total Wine anchored center to 100%. In addition, Whitestone added Vishala Foods, specializing in spices and produce used in Indian cuisine, at Sugar Park Plaza. Whitestone CEO, Dave Holeman, commented, "Our bringing Lake Woodlands Crossing from 89% occupancy to 100% occupancy in under a year reflects our leasing team's ability to add value using local knowledge and technology. We continue to see a strong leasing environment in Texas and Arizona as consumers continue to frequent the service-oriented businesses of tenants at our centers."

08:44 EST Trupanion appoints Enthoven to board of directors - Trupanion has appointed Richard Enthoven, Director at PetSure Australia and Hollard Holdings Australia, as an independent director to the Company's Board of Directors, effective today.

08:43 EST Qualigen Therapeutics announces first patient dosed in Phase 1a trial of QN-302 - Qualigen Therapeutics announces that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors. The first clinical site is located at START Midwest in Grand Rapids, Michigan. The QN-302 Phase 1 clinical trial is multi-site, open-label, dose-escalation and dose expansion, safety, pharmacodynamic and pharmacokinetic study of intravenous QN-302 in patients with advanced or metastatic solid tumor. "The initiation of the QN-302 Phase 1a clinical trial represents a significant milestone for Qualigen and further progress toward our goal to offer patients new treatment options for devastating diseases, such as pancreatic cancer and other advanced solid tumors," commented Tariq Arshad, M.D., M.B.A., Qualigen's Chief Medical Officer. "We are grateful for the support of our CRO, TD2, as well as study sites, investigators, and patients and families who are all working together to explore the potential of QN-302 as a novel treatment for G4-prevalent tumors. We look forward to continuing these close partnerships as we enroll additional patients in our Phase 1a study."

08:41 EST Fortune Rise Acquisition receives extension to complete business combination - Fortune Rise Acquisition announced that Water On Demand Inc., a privately-held subsidiary of OriginClear and owner of its sponsor, Fortune Rise Sponsor, has deposited the required $100,000 into the Company's trust account for the benefit of its valued public stockholders which provides a one-month extension to complete the Company's initial business combination. This additional contribution extends the date by which the Company has to complete its initial business combination for an additional one-month extension from November 5, 2023 to December 5, 2023. The extension is the first of the twelve one-month extensions permitted under the Company's governing documents, as amended in October 2023. Such contribution effectively increases the pro rata portion of the funds available in the Company's trust account in the event of the consummation of an initial business combination, liquidation, or other redemption event, by $0.032 per share. The contribution was funded as a non-interest bearing loan that will either be paid upon earlier of consummation of an initial business combination or the Company's liquidation.

08:40 EST SOBR Safe secures first mental health customer - SOBR Safe has secured its first mental health customer, The Mental Health Collective. Based in in Newport Beach, California, The Collective is initially installing SOBRcheck to replace breathalyzers for routine alcohol screening in one of its four facilities. Upon successful implementation, The Collective intends to roll out SOBRcheck to its other locations.

08:38 EST Bitdeer mines 462 bitcoin in October - Linghui Kong, Chief Executive Officer of Bitdeer, commented, "We continued to maintain a stable hash rate and aggregate electrical capacity during the month of October, and once again demonstrated solid results. On a strategic level, our team remains committed to identifying and pursuing initiatives which can leverage our existing expertise and take our tech capabilities to the next level. In terms of infrastructure, since entering full operations in September, our Gedu Datacenter in Bhutan has continued to function smoothly, augmenting our existing capabilities and contributing to our strong performance. During October, the Gedu Datacenter provided us with 3.3EH/s hash rate, and 211 Bitcoins were mined there, representing approximately 46% of our total Bitcoins mined for the month. Meanwhile, on the expansion front, we advanced construction of a 175MW immersion cooling datacenter at our Tydal, Norway mining facility, which we expect will be complete in 2025. Going forward, we will remain dedicated to pursuing strategic developments which will boost our long-term success, and we are confident that we will build lasting, sustainable value for our shareholders."

08:38 EST Strong Global Entertainment acquires Innovative Cinema Solutions - Strong Global Entertainment announced that the Company entered into an asset purchase agreement on November 3, 2023, with Innovative Cinema Solutions, a full service provider of technical services and solutions to national cinema chains. The operations of ICS will be rolled into SGE's wholly-owned subsidiary, Strong Technical Services, which provides comprehensive managed service offerings with 24/7/365 support nationwide to ensure solution uptime and availability. Mark Roberson, CEO of SGE, added, "The acquisition of ICS marks our second acquisition since going public in May of this year. We believe this acquisition not only adds meaningful revenue and scale but is also highly synergistic to our service offerings and customer relationships."

08:37 EST Thumzup welcomes WeHo Bistro to cash rewards platform - Thumzup Media welcomes WeHo Bistro, located on 1040 N. La Cienega Blvd. West Hollywood, CA 90069, to its cash rewards digital social media branding platform.

08:35 EST ClearSign appoints Matthew Martin as Chief Technology Officer - ClearSign hired Matthew Martin as Chief Technology Officer. Martin has over 20 years of experience in combustion-related industries. Before joining ClearSign, he served as the Chief Research Scientist at XRG Technologies. During his tenure at Honeywell from 2009 to 2018, he held various positions, including Senior Product Line Manager for Burners, Flares, Flare Gas Recovery, and Thermal Oxidizers. From 2000 to 2009, Martin worked at Callidus Technologies in roles such as CFD Analyst, Design Engineer, and Software Developer. In connection with Martin's hire, on November 6, the company, granted non-qualified stock options to purchase an aggregate of 150,000 shares of its common stock. The options were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to Martin's entering into employment with the company. The options have an exercise price of 91c per share. The options will vest in three equal installments, with one third of the options vesting on the grant date, and each remaining third of the options will vest on the second and third anniversaries of the grant date.

08:34 EST Bragg Gaming extends agreement with Entain in the Netherlands - Bragg Gaming (BRAG) announced it has extended its agreement with Entain (GMVHF) to supply Entain's Dutch iGaming operator, BetCity.nl, with the company's player account management, or PAM, platform until 2025. BetCity.nl will also continue to utilize Bragg's content and product delivery services on an exclusive basis for the duration of the extended PAM agreement, allowing Bragg to provide its proprietary, exclusive and aggregated casino content as well as the delivery of sports betting products to customers of the leading Dutch market operator. In addition, Bragg will integrate with several new iGaming suppliers to further enhance the localized content portfolio the company provides to the Netherlands market.

08:31 EST BTU Metals commences airborne geophysical survey at Dixie Halo - BTU METALSCORP. is pleased to provide the following update. Pursuant to the option agreement with Kinross Gold Corporation, BTU and Kinross continue to work towards establishing a more robust understanding of the geological setting at BTU's Dixie Halo project located in the Great Bear Gold discovery part of the Red Lake Mining district. Near-term exploration activities include undertaking a comprehensive airborne magnetic geophysical survey, essentially identical to the one completed on the adjacent Great Bear property in 2017. The new survey which will cover much of the original Dixie Halo property is scheduled to commence this week and this data will provide a seamless grid of very high-quality magnetic data connecting with the historical survey data over the Great Bear Dixie property. High quality magnetic data was one of the exploration tools used by Great Bear Resources in defining the potential location of gold mineralization. Kinross made a firm commitment to the Great Bear gold discovery area when they paid approximately C$1.8 billion to take over Great Bear Resources Ltd. and they continue to invest significant additional capital in the project as they expand exploration efforts to more fully understand the extent and amount of gold on the Great Bear project while, at the same time, working toward developing a significant new high-grade open pit and underground gold mine on the Great Bear property located immediately to the north of the Company's Dixie Halo project.

08:28 EST Verisk Analytics announces Citizens adopted Aerial Imagery Analytics - Verisk announced that Citizens Property Insurance Corporation, a not-for-profit insurer in Florida, will adopt Verisk's Aerial Imagery Analytics solution to help provide a more comprehensive view of risks across the state. Verisk submitted a proposal to provide the service to Citizens, which evaluated the solution against competing vendors for analytic breadth and accuracy. Verisk collaborates with Vexcel Data Program, the world's largest aerial imagery program, to source imagery and elevation models and then Verisk applies computer vision machine learning to derive its library of imagery analytics for P&C insurers.

08:27 EST Verizon Public Sector enters CRADA with Dept. of Veterans Affairs - Verizon Public Sector has entered into a Cooperative Research and Development Agreement with the United States Department of Veterans Affairs, VHA IE National Center for Collaborative Healthcare Innovation at the VA Palo Alto Health Care System to help provide broadband connectivity directly to Veterans living in remote areas. This targeted internet availability will provide VAPAHCS Veterans access to resources that may not otherwise be available, perhaps most notably telehealth and telewellness - areas the VA has identified as high priorities. This groundbreaking project has begun at the VA Palo Alto Health Care System, a network known for delivering next-generation healthcare solutions now for Veterans.

08:25 EST Kaival Brands provides update on regulatory landscape e-cigarette, vaping - Kaival Brands Innovations Group provided an update on the evolving regulatory landscape of the e-cigarette and vaping industry. As the exclusive U.S. distributor of products manufactured by Bidi Vapor, which are fully compliant with all current FDA regulations, Kaival Brands is positioned at the forefront of the market as the FDA intensifies its enforcement actions against non-compliant and illicit e-cigarette products. In light of the U.S. International Trade Commission's ongoing efforts to address unfair imports and sales practices in the vaping sector, Kaival Brands underscores the importance of such regulatory actions in maintaining a fair and lawful marketplace. The ITC's role in investigating and potentially issuing exclusion and cease and desist orders against illicit imports is a critical component in the fight against the unauthorized e-cigarette market. "As the FDA continues to clear the market of illicit and non-compliant e-cigarette products, Kaival Brands stands ready to meet the demand for legal and regulated alternatives," said Eric Mosser, President and CEO of Kaival Brands. "Our commitment to compliance and excellence positions us to capture a significant market share as the FDA's enforcement actions take effect."

08:23 EST Centrus Energy makes first HALEU delivery to U.S. DoE - Centrus Energy announced that it has made its first delivery of High-Assay, Low-Enriched Uranium HALEU to the U.S. Department of Energy, completing Phase One of its contract with the Department by successfully demonstrating its HALEU production process. Centrus will now move on to Phase Two of the contract - requiring a full year of HALEU production at the rate of 900 kilograms per year at its American Centrifuge Plant in Piketon, Ohio. "Centrus is proud to be pioneering American HALEU production, with our first delivery of the fuel that is urgently needed to support the demonstration and commercialization of advanced reactors," said Centrus President and CEO Daniel B. Poneman. "This critical milestone is essential to meeting the Department's near-term HALEU needs, while laying the groundwork for the full restoration of America's lost domestic uranium enrichment capacity. We are committed to working with the Department and industry to build a public-private partnership so that we can scale up production in the coming years to meet the full range of commercial and national security requirements for enriched uranium." "Our HALEU team has worked exceptionally hard to complete this project ahead of schedule and under budget - showing we can execute on big, complicated projects and deliver value to our customers," said Centrus Senior Vice President of Operations Larry Cutlip. "We are grateful to have had the opportunity to demonstrate and expand our capabilities and expertise over the course of this work and look forward to embarking on the next phase of this important effort." .

08:22 EST Oryzon Genomics announces last patient visit in Phase IIb PORTICO study - Oryzon Genomics announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat's efficacy in Borderline Personality Disorder. PORTICO is a global double-blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial evaluating the efficacy and safety of vafidemstat in a BPD population. The trial has two primary endpoints: reduction of agitation and aggression and overall disease improvement in BPD severity. As independent multiple primary endpoints, statistical significance in either one is sufficient to declare success in the trial. The trial has opened a total of 27 clinical sites, 14 in the U.S. and 13 in Europe, and has recruited a total of 210 patients, randomized 1:1 in two arms. Last March, a pre-specified Interim Analysis qualified PORTICO as non-futile and recommended that the trial should continue as it is without increasing the number of patients to be recruited. The independent Data Monitoring Committee has met routinely and reviewed unblinded safety data throughout the PORTICO trial. The last analysis corresponded to the initial 198 randomized patients and the DMC recommended continuing the trial without modifications until full enrollment, Current safety data of PORTICO are aligned with previous vafidemstat trials and continue to support that vafidemstat is safe and well-tolerated. Topline results are expected in Q1 2024, followed by a full data presentation at a psychiatric conference and in a peer-reviewed journal publication.

08:20 EST 23andMe launches Total Health, a new health membership - 23andMe Holding launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care. Members of Total Health will also receive all the reports and features offered in the Company's existing 23andMe+ Premium Membership. Total Health delivers on 23andMe's mission to help people access, understand and benefit from the human genome. This membership is for individuals who want to augment their current healthcare experience with even more direct access to comprehensive genetic testing, blood biomarker testing, risk assessment in critical health areas, and personalized health plans driven by clinicians trained in genetics. "We're bringing the power of genetics into your personal healthcare journey, along with blood biomarkers, personal and family health history and lifestyle to help you understand the full picture of your disease risks," said 23andMe's Vice President of Genomic Health Noura Abul-Husn, M.D. Ph.D. "We're also helping you understand what to do with this information through clinician consultations and ongoing access to medical professionals. We believe this type of comprehensive approach to prevention will lead to longer, healthier lives."

08:18 EST ReWalk Robotics to discuss payment determination for Personal Exoskeleton - ReWalk Robotics has scheduled a conference call for Wednesday, November 8, 2023 at 8:30 a.m. EST, to discuss Medicare's preliminary payment determination for the ReWalk Personal Exoskeleton. On Friday, November 3, the Centers for Medicare & Medicaid Services released an agenda for the upcoming Healthcare Common Procedure Coding System meeting on November 29, 2023, which includes an item to discuss the Medicare payment determination for the ReWalk Personal Prosthetic Exoskeleton system and provides a preliminary payment determination of $94,617.

08:17 EST NeuroOne Medical responds to FDA questions on OneRF Ablation System submission - NeuroOne Medical Technologies has responded to the Food and Drug Administration's questions regarding the Company's previous submission of a 510(k) for its OneRF Ablation System. The Company expects to receive additional communication back from the FDA in thirty days or less. The OneRF system uses the already implanted sEEG electrodes to record brain activity and allow for ablation of nervous tissue when connected to the Company's proprietary radio frequency generator. If cleared by the FDA, NeuroOne's OneRF 510(k) submission represents the first step in bringing to market an innovative RF ablation system in the field of neurology and neurosurgery. As the Company's first therapeutic device, OneRF is a combination system that includes both diagnostic and therapeutic capabilities. The system utilizes a customized RF generator with real-time temperature monitoring capabilities, allowing clinicians to have greater control over temperature management during the ablation. Designed to both record brain activity and ablate nervous tissue using the same electrode, the system is designed to offer the potential for a safer clinical option for patients as well as lower costs by reducing the number of invasive procedures and hospital stays for patients. NeuroOne estimates the current brain ablation market to be at least $100M worldwide and growing rapidly, with the potential to grow multiple fold based on large addressable patient populations with unmet clinical needs.

08:16 EST Treasure Global's Abe Yus to supply curry puffs to convenience store chain - Treasure Global announced that Abe Yus Malaysia announced its expansion plan to supply its best-selling curry puffs to the world's largest convenience store. This strategic move marks a significant milestone in diversifying the group's product offering channels and extending its distribution reach. The first phase of expansion will focus on supplying the high-selling curry puffs to 250 convenience stores in Malaysia. Subsequent phases will encompass additional store locations and introduce more products, signifying notable expansion into the F&B market, tapping into a new revenue stream through the extensive network of convenience stores. Abe Yus' F&B group of businesses include the popular "Kari Puffs" from grab and go food carts, as well as the Abe Yus Warung Street food kiosks, Abe Yus Cafe restaurants, and Abe Yus Marts B2C online e-commerce delivery service. The chain currently has 12 outlets operating across Malaysia, with plans to open 35 outlets by the end of 2023 and 300 outlets to be opened over the next five years in the country. In addition, Abe Yus plans to expand further into the Southeast Asian market in the future.

08:14 EST Sunrun provides Affordable Housing community with clean energy savings - BLDG Partners, the Foundation for Affordable Housing, the City of Orange and Southern California Edison partnered with Sunrun for a ribbon-cutting ceremony to celebrate a new solar installation at The Knolls, an affordable housing community in Orange, California. The project-one of the largest affordable housing solar installations to be completed in California-provides solar energy credits to 260 apartment homes and saves each family an average of $60 per month on their electricity bills through virtual net metering. Over the next 20 years, the system is projected to save over $6 million for the low-income residents. "Everyone deserves access to affordable, abundant, and predictably priced clean energy," said Sunrun CEO Mary Powell. "Sunrun is dedicated to advancing energy equity, which is particularly impactful for lower-income communities and renters that value energy security and stability. We take great pride in delivering clean energy and substantial monthly bill savings to the residents of The Knolls."

08:09 EST Harmonic's broadband platform selected by Okinawa Cable Network in Japan - Harmonic announced that Okinawa Cable Network - OCN - in Japan is using Harmonic's cOS broadband platform to deliver high-speed internet service to subscribers. OCN has deployed Harmonic's cOS broadband platform in a distributed access architecture with Harmonic's Reef Remote PHY DAA shelves to address capacity issues.

08:00 EST i-80 GOLD signs non-binding term sheet for JV of Ruby Hill - i-80 Gold announces that it has entered into a non-binding term sheet in connection with a potential joint venture with an arm's length third party pursuant to which such potential partner will acquire a minority interest in the Company's Ruby Hill Property located in Eureka County, Nevada. Reports recent drill results from expansion of polymetallic mineralization:19.4 % Zn & 19.2 g/t Ag over 30.4 m,iRH23-18A - Blackjack Skarn...

07:53 EST Nextech3D.AI partners with Pixelloid Studios for 3D artists - Nextech3D.AI announced a partnership with Pixelloid Studios. Pixelloid has already graduated over 3000 students. Through this partnership, Nextech3D.ai is gaining access to a large talented and trained pool of students that have graduated from Pixelloid's advanced 3D training program. This partnership represents an essential step in Nextech3D.ai's ongoing efforts to address the increasing demand for 3D models from Amazon and others. Recognizing the surging demand for 3D models and the necessity to scale production, Nextech3D.ai has strategically chosen Hyderabad, India as the site for this expansion. Pixelloid Studios, who also has offices in Hyderabad will play a pivotal role in this initiative by training a team of skilled 3D model artists, who will integrate seamlessly into Nextech3D.ai's workforce in India. Nextech3D.ai sees these efforts as significantly enhancing its 3D model production capacity at lower costs, thus positioning the company for success in 2024.

07:50 EST Regulus delivers phase two metallurgical samples to Nuton - Regulus Resources has delivered samples to Nuton, a Rio Tinto venture, to begin the phase two metallurgical program utilizing Nuton's proprietary primary sulphide leaching technologies. The phase one metallurgical program determined that mineralization from AntaKori was amenable to Nuton's sulphide leaching technologies, while the phase two program is designed to expand on the results from phase one and refine the understanding regarding metallurgical recoveries for various styles of mineralization.

07:49 EST Cognition Therapeutics completes enrollment in Phase 2 SHINE study - Cognition Therapeutics announced that the last participant was randomized in the Phase 2 SHINE study of CT1812, the company's lead candidate for the treatment of age-related neurodegenerative diseases of the CNS and retina. A total of 153 adults with mild-to-moderate Alzheimer's disease were randomized to receive either placebo or oral doses of CT1812. Endpoints include safety, change in cognitive function, as measured by ADAS-Cog 11 and biomarker evidence of disease modification. Top-line results are expected in mid 2024 after the last participants have completed six months of treatment. "Results of the SHINE trial will provide important information on safety, tolerability and cognitive effects of CT1812 in people with mild-to-moderate Alzheimer's disease, and these results will inform our plans for Phase 3 development," Lisa Ricciardi, president and CEO of Cognition Therapeutics stated. "Completing enrollment in the trial ahead of our 2023 target allows us to bring proof-of-concept results sooner and provides savings to our company. We couldn't have accomplished this without the support of the study participants and caregivers as well as our investigators and collaborators at the National Institute on Aging. We look forward to seeing the full study results in mid 2024." An evaluation of the first 24 SHINE participants showed that those treated with CT1812 experienced a slowing of cognitive decline as measured by a three-point difference on the ADAS-Cog 11 scale compared to placebo. Overall, CT1812 was well tolerated and adverse events were balanced across treatment groups, consistent with the safety profile observed in previous clinical trials.

07:47 EST Jazz Pharmaceuticals and MD Anderson Center partner for zanidatamab in cancer - Jazz Pharmaceuticals and The University of Texas MD Anderson Cancer Center announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers. The collaboration will combine MD Anderson's translational medicine and clinical research expertise with Jazz's expanding oncology drug development capabilities to investigate the potential of zanidatamab as monotherapy and in combination with other treatments for patients with different tumor types and stages. This includes its possible applicability in early-stage breast cancer, treatment areas where other HER2-directed therapies have failed, cancers with varying degrees of HER2-expression, and potentially rare, tissue-agnostic cancers. Jazz and MD Anderson will establish a joint steering committee to oversee the collaboration, which will fund multiple studies over its five-year term. Research under the collaboration is expected to begin in late 2023 or early 2024.

07:46 EST Matinas BioPharma announces in vivo efficacy results of oral LNC docetaxel - Matinas BioPharma announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, a well-known chemotherapeutic agent used in the management of multiple metastatic and unresectable tumors. Currently, docetaxel is administered intravenously and can be associated with significant side effects and toxicities. "We are excited to report new in vivo data demonstrating the therapeutic efficacy of an oral LNC formulation of docetaxel," said Dr. James Ferguson, Chief Medical Officer of Matinas. "We believe this is a step forward for Matinas' unique drug delivery platform, taking us beyond our successes in infectious disease by providing convincing proof-of-principle that orally administered LNCs can effectively target tumors and successfully deliver small molecule therapeutics to those tumors." Key Findings: Efficacy: Anti-tumor effect of daily oral LNC docetaxel in both the high-dose and low-dose arms were comparable to IV docetaxel with statistically significant reductions in tumor volume compared with untreated controls at Day 14, and similar reductions in tumor weight at Day 14. Safety: No systemic toxicities were noted. Body weight was stable over treatment duration and hematologic parameters were similar to untreated controls.

07:43 EST PolyPid appoints Nurit Tweezer-Zaks to board of directors - PolyPid announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks currently serves as CEO of MediCane Health, a fully-integrated global medical cannabis company.

07:42 EST Glencore completes acquisition of PolyMet - PolyMet Mining (PLM) announces that it has completed the transactions contemplated by the previously announced statutory plan of arrangement under Part 9, Division 5 of the Business Corporations Act involving the Company and Glencore AG (GLNCY). Pursuant to the Arrangement, Glencore acquired the approximately 17.82% of the issued and outstanding common shares of PolyMet that Glencore did not already own for US$2.11 in cash, per Minority Share. PolyMet has applied to have its common shares delisted from the Toronto Stock Exchange and the NYSE American and has applied to cease to be a reporting issuer under Canadian securities laws. Once PolyMet ceases to be a reporting issuer, the Company will no longer be subject to the ongoing continuous disclosure and reporting obligations currently imposed upon the Company as a reporting issuer under such legislation.

07:40 EST Generac selected by Department of Energy as qualified vendor in Puerto Rico - Generac has been selected by the U.S. Department of Energy as one of several qualified vendors to enter award negotiations as part of an up to $440M investment from the Puerto Rico Energy Resilience Fund. This funding will support residential solar and battery storage systems for up to 40,000 vulnerable Puerto Rican households with installations to potentially start in the spring of 2024. Generac will be working with local partners to support the program.

07:33 EST Arbutus Biopharma announces CEO Collier to retire, McElhaugh to be interim CEO - Arbutus Biopharma Corporation announced that William Collier will retire from his position as the Company's President and Chief Executive Officer, and as a member of the Board of Directors, at the end of 2023. Michael McElhaugh, Co-founder and Chief Operating Officer of Arbutus, will serve as Interim President and Chief Executive Officer, effective January 1, 2024. McElhaugh will also join the Board at that time. Collier and McElhaugh will work together closely to ensure a smooth transition.

07:29 EST BeyondSpring presents new data on plinabulin's immunomodulating activity - BeyondSpring announced new data that translates preclinical proof-of-concept to clinical evidence of plinabulin's immunomodulating activity. BeyondSpring and MD Anderson presented the data at the Society for Immunotherapy of Cancer's, SITC, 38th Annual Meeting on Nov 4th in San Diego, CA on an open-label, Phase 1 basket study at The University of Texas MD Anderson Cancer Center in cancer patients after progressing on PD-1, PD-L1 and/or CTLA-4 antibodies in six cancer types. Based on preclinical models, where plinabulin plus radiation and anti-PD-1 antibody enhances dendritic cell activation, T-cell proliferation, and abscopal effect, a clinical study was initiated to test these findings. At the Phase 1 data cut-off, 19 heavily pretreated patients with 6 different cancers were exposed to plinabulin after radiation initiation to an amendable lesion plus anti-PD-1 antibody, including pembrolizumab or nivolumab. 11 out of 14 patients eligible for efficacy assessment per RECIST criteria and had measurable target lesion responses in the non-irradiated tumor lesion. Disease control rate evaluates the tumor reduction in non-irradiated tumor to assess abscopal effect from immune agents. 80% DCR in non-irradiated tumor: In 10 immunotherapy-refractory patients of 6 different cancers, plinabulin triple combination is safe and yields encouraging response with 80% disease control rate. Durable Response in heavily pre-treated patients: 2 Hodgkin's lymphoma patients who progressed after 12 or 16 prior lines of therapy respectively, had durable responses with one PR and one SD. These patients continued treatment after data cutoff. DC maturation in responding patients: Plinabulin administered after radiation initiation induces an early systemic immune response in subsets of peripheral blood DC and monocytes in patients with clinical benefits. Plinabulin mediates GEF-H1-dependent immune activation in responding patients: In patients with PR+SD, tumor scRNAseq analysis indicates GEF-H1-dependent immune activation in subsets of DC and monocyte-derived macrophages. Such activation was not seen in patients with PD. Additional biomarker analyses at baseline and post-treatment are underway.

07:27 EST Stella-Jones announces normal course issuer bid - Stella-Jones announced that the Toronto Stock Exchange has accepted its Notice of Intention to Make a Normal Course Issuer Bid. Pursuant to the Notice, Stella-Jones may, during the 12-month period commencing November 14, 2023, and ending November 13, 2024, purchase for cancellation, up to 2,500,000 Common Shares, representing approximately 5% of the public float of its Common Shares. As at October 31, 2023, Stella-Jones had 57,153,679 Common Shares issued and outstanding, 49,446,375 Common Shares comprising the public float. As approved by the TSX, the Company was authorized to purchase for cancellation up to 5,000,000 Common Shares during the 12-month period commencing on November 14, 2022 and ending on November 13, 2023. During the period commencing November 14, 2022 and ending October 31, 2023, the Company purchased 2,426,452 Common Shares through the facilities of the TSX at a weighted average price of approximately $57.62 per Common Share, for a total consideration of approximately $139,802,149. The Notice provides that purchases under the Normal Course Issuer Bid will be effected on the open market through the facilities of the TSX. The average daily trading volume of the Common Shares on the TSX for the six-month period ended October 31, 2023 was 116,080 Common Shares and, therefore, in accordance with the requirements of the TSX, the daily purchase limit under the NCIB on the TSX will be 29,020 Common Shares, representing 25% of the ADTV, subject to certain prescribed exceptions. The price that Stella-Jones will pay for any Common Shares acquired by Stella-Jones under the NCIB will be the market price of the Common Shares at the time of acquisition. Purchases will be made at management's discretion. Additionally, Stella-Jones has implemented an automatic share purchase plan with its designated broker in connection with the NCIB in order to allow, if deemed advisable by Stella-Jones, for share purchases during self-imposed blackout periods. The Board of Directors of Stella-Jones believes that the repurchase of Common Shares represents an attractive and responsible investment of capital and is in the best interests of Stella-Jones.

07:24 EST Sterling Check, Konfir partner for employment verifications in the UK - Sterling Check and Konfir are partnering to enhance Sterling's background screening process. Sterling will combine its deep market expertise and unrivaled client service with the latest in employment verification technology, leveraging Konfir's permission-driven process that enables candidates to share payroll, tax, and open banking data instantly via desktop or mobile devices.

07:19 EST Rhythm Pharmaceuticals announces near-term milestones - Rhythm also expects to achieve the following near-term milestones: Complete patient enrollment in the pivotal Phase 3 clinical trial in hypothalamic obesity in the fourth quarter of 2023; Complete submission to the U.S. Food and Drug Administration of an investigational new drug application for RM-718, a new, weekly, MC4R-specific agonist, in the fourth quarter of 2023. RM-718 is designed to be more targeted and potent than setmelanotide, and designed to be MC1R sparing, with the potential to not cause hyperpigmentation; Announce preliminary data from the open-label part of the Phase 2 DAYBREAK trial from approximately five genetically-defined cohorts in the fourth quarter of 2023; Announce topline data from the ongoing Phase 3, open-label pediatrics trial evaluating one year of setmelanotide therapy in patients with MC4R pathway deficiencies between the ages of 2 and 6 years old in the fourth quarter of 2023; and Provide pharmacokinetic and tolerability data from the ongoing Phase 3 switch trial evaluating a weekly formulation of setmelanotide in the fourth quarter of 2023. Today, Rhythm announced plans to provide an update on several R&D programs during a breakfast event for investors and analysts on December 6, 2023 in Boston.

07:12 EST Entrada Therapeutics expects cash to fund requirements through 2025 - Cash, cash equivalents and marketable securities were $353.6 million as of September 30, 2023, compared to $188.7 million as of December 31, 2022. Entrada anticipates that its cash, cash equivalents and marketable securities as of September 30, 2023, together with Vertex collaboration ongoing research support and the anticipated achievement of certain milestones, will be sufficient to fund the Company's operating expenses and capital expenditure requirements through 2025.

07:10 EST ADC Therapeutics expects cash runway to extend into middle of 2025 - Cash and cash equivalents were $310.4 million as of September 30, 2023, compared to $326.4 million as of December 31, 2022. The Company continues to expect its cash runway to extend into the middle of 2025.

07:02 EST iTeos Therapeutics expects cash to provide runway through 2026 - The Company's cash, cash equivalents, and investments position was $644.9 million as of September 30, 2023, as compared to $752.2 million as of September 30, 2022. The Company continues to expect its cash balance to provide runway through 2026.

06:40 EST D.R. Horton reports Q4 net sales orders increased 39% to 18,939 homes - Net sales orders increased 39% to 18,939 homes and 34% in value to $7.3B. Donald Horton, Chairman of the Board, said, "The D.R. Horton team finished the year strong, highlighted by fourth quarter consolidated pre-tax income of $2.0 billion on a 9% increase in revenues and a pre-tax profit margin of 19.2%. For the year, our consolidated pre-tax income was $6.3 billion on a 6% increase in revenues and a pre-tax profit margin of 17.8%. With a record 89,092 homes closed by our homebuilding and single-family rental operations in fiscal 2023, D.R. Horton completed its 22nd consecutive year as the largest homebuilder in the United States. These results reflect the strength of our experienced operators, industry-leading market share and broad geographic footprint. Despite continued higher mortgage rates and inflationary pressures, our net sales orders increased 39% from the prior year quarter, as the supply of both new and existing homes at affordable price points remains limited and demographics supporting housing demand remain favorable. We are well-positioned to meet changing market conditions with our affordable product offerings and flexible lot supply and are focused on turning our inventory to maximize returns and capital efficiency in each of our communities. Our cash flow from operations in fiscal 2023 was $4.3 billion, and our consolidated leverage at the end of the year was 18.3%, the lowest in Company history. Our strong balance sheet, liquidity and low leverage provide us with significant financial flexibility, and we plan to maintain our disciplined approach to investing capital to enhance the long-term value of our company, including returning capital to our shareholders through both dividends and share repurchases on a consistent basis."

06:36 EST Sage Therapeutics expects cash, equivalents and securities sufficient into 2026 - Sage expects that, based on its current estimates, its current cash, cash equivalents and marketable securities, along with anticipated funding from ongoing collaborations, collaboration revenue from sales of ZURZUVAE, and a potential milestone payment of $75.0M from Biogen for the first commercial sale of ZURZUVAE for the treatment of women with PPD, will support operations into 2026. Additionally, Sage underwent a strategic reorganization and pipeline reprioritization in August 2023. The company expects annualized net savings of approximately $240M, of which 60% is related to R&D. The annualized net savings include $100M related to the workforce reduction.

06:22 EST UBS: Outlook for economic growth, asset valuations remains difficult to predict - The company said, "Central banks have paused interest rate increases, but uncertainties remain in terms of the appropriate level of interest rates that will allow inflation to converge to their targets. As a result, the outlook for economic growth, asset valuations and market volatility remains difficult to predict. In addition, the ongoing geopolitical tensions including the conflicts in the Middle East and Ukraine continue to cloud the macroeconomic outlook. This, in addition to normal seasonality, may affect wealth management and institutional clients' transactional activity in the fourth quarter of 2023. We also expect clients to continue to shift cash holdings from deposits into higher-yielding products, resulting in similar sequential net interest income performance. As we continue to execute on our strategy, growth and integration plans, our focus remains on offsetting some of these ongoing challenges by helping clients to manage the inherent risks and opportunities, gaining share of wallet and actively winding down our non-core assets and costs."

06:20 EST Radware expands relationship with Asia-Pacific government technology office - Radware announced it is providing expanded security services for a leading Asia-Pacific government office that is chartered to oversee its nation's information technology infrastructure and services. The office is focused on strengthening cyber defenses across its data center infrastructure and ensuring secure delivery of government services to its growing user base. The multimillion-dollar deal, which represents the extension of an existing relationship, includes the purchase of Radware's Alteon application delivery controller and Alteon Global Elastic License. The office previously deployed Radware's DefensePro DDoS Protection.

06:14 EST Meta Platforms stops political advertisers from using generative AI tools - The company said, "As we continue to test new Generative AI ads creation tools in Ads Manager, advertisers running campaigns that qualify as ads for Housing, Employment or Credit or Social Issues, Elections, or Politics, or related to Health, Pharmaceuticals or Financial Services aren't currently permitted to use these Generative AI features. We believe this approach will allow us to better understand potential risks and build the right safeguards for the use of Generative AI in ads that relate to potentially sensitive topics in regulated industries." Reference Link

06:08 EST Oscar Health raises 2023 adjusted EBITDA view to ($60M)-($50M) - Had previously seen ($175M)-($75M).

05:32 EST WeWork files for bankruptcy in the U.S., recognition proceedings in Canada - WeWork announced that it has commenced a reorganization to strengthen its capital structure and financial performance. The company has entered into a restructuring support agreement, or RSA, with holders representing approximately 92% of its secured notes to reduce the company's existing funded debt and expedite the restructuring process. During this period, WeWork will further rationalize its commercial office lease portfolio while focusing on business continuity as global operations are expected to continue as usual. WeWork and certain of its entities filed for protection under Chapter 11 of the U.S. Bankruptcy Code, and intend to file recognition proceedings in Canada under Part IV of the Companies' Creditors Arrangement Act. WeWork's locations outside of the U.S. and Canada are not part of this process. WeWork's franchisees around the world are similarly not affected by these proceedings. WeWork has a lease rejection plan that is expected to position the company for operational and financial success. As part of today's filing, WeWork is requesting the ability to reject the leases of certain locations, which are largely non-operational and all affected members have received advanced notice. WeWork is filing with the court a series of customary "First Day Motions" to facilitate a transition into the process and to support operations throughout its cases, which it expects to be approved in short order. The company will continue servicing its existing members, vendors, partners, and other stakeholders in the ordinary course of business. WeWork expects to have the financial liquidity to execute these proceedings and continue business in the ordinary course.

05:18 EST HP Inc. enters strategic pact with Indo-MIM for metal additive manufacturing - HP Inc. announced a strategic partnership with Indo-MIM. This collaboration marks a step toward advancing metal additive manufacturing technology and expanding its applications in various industries. Indo-MIM has initially invested in three cutting-edge HP Metal Jet S100 printers as part of this collaboration, strengthening their commitment to advancing additive manufacturing globally. Two of three printers will be stationed at Indo-MIM's Bangalore, India facility. One of them will focus on new material development, while the other will be driving application development and cater to customers in the Middle East, India and the rest of the Asia-Pacific region. The third unit will be based in Texas, USA, reinforcing Indo-MIM's commitment to providing localized support for North American clients and expanding their production capabilities.

05:13 EST VMware enters private AI collaboration with Intel - VMware (VMW) announced a collaboration with Intel (INTC) to extend the companies' more than two decades of innovation to help customers accelerate the adoption of artificial intelligence, or AI, and enable private AI everywhere, across data centers, public clouds, and edge environments. VMware and Intel are working to deliver a jointly validated AI stack that will enable customers to use their existing general-purpose VMware and Intel infrastructure and open source software to simplify building and deploying AI models. The combination of VMware Cloud Foundation and Intel's AI software suite, Intel Xeon processors with built-in AI accelerators, and Intel Max Series GPUs, will deliver a validated and benchmarked AI stack for data preparation, model training, fine-tuning and inferencing to accelerate scientific discovery and enrich business and consumer services.